Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
| ▸ | PLK4 | O00444 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | ROS1 | P08922 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | FLT1 | P17948 | 1/20 | 0.55 |
| ▸ | MARK3 | P27448 | 1/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | CLK2 | P49760 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31428636 | 1.00 | GHSR (0.65) | GHSRALDH1A1HSD17B10MAPTMAPK14 | |
| SCHEMBL31428795 | 0.90 | MAPK14 (0.60) | GHSRALDH1A1HSD17B10MAPTMAPK14 | |
| SCHEMBL22216392 | 0.90 | MAPK14 (0.60) | GHSRALDH1A1HSD17B10MAPTMAPK14 | |
| SCHEMBL29944074 | 0.85 | GHSR (0.71) | GHSRALDH1A1HSD17B10MAPTMAPK14 | |
| SCHEMBL1355458 | 0.85 | GHSR (0.71) | GHSRALDH1A1HSD17B10MAPTMAPK14 | |
| SCHEMBL29990457 | 0.84 | GHSR (0.67) | GHSRALDH1A1HSD17B10MAPTMAPK14 | |
| SCHEMBL3235960 | 0.84 | GHSR (0.67) | GHSRALDH1A1HSD17B10MAPTMAPK14 | |
| SCHEMBL17443852 | 0.84 | GHSR (0.75) | GHSRALDH1A1HSD17B10MAPTMAPK14 | |
| SCHEMBL2207578 | 0.82 | GHSR (0.65) | GHSRALDH1A1HSD17B10MAPTMAPK14 | |
| SCHEMBL16002856 | 0.82 | GHSR (0.69) | GHSRALDH1A1HSD17B10MAPK14HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106660996-B | 2, 5-substituted pyrimidines as PDE4 inhibitors | 格吕伦塔尔有限公司 | 2020-10-16 | — | — | CN | disclosed |
| US-10391099-B2 | Method of treating psoriatic arthritis, psoriasis, and chronic obstructive pulmonary disease with a novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| EP-3415510-A1 | NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE4 INHIBITORS | Grünenthal GmbH (DE) | 2018-12-19 | — | — | EP | disclosed |
| EP-3415509-A1 | NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE INHIBITORS | Grünenthal GmbH (DE) | 2018-12-19 | — | — | EP | disclosed |
| EP-3169679-A1 | NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE4 INHIBITORS | Grünenthal GmbH (DE) | 2017-05-24 | — | — | EP | disclosed |
| EP-3169680-A1 | NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE INHIBITORS | Grünenthal GmbH (DE) | 2017-05-24 | — | — | EP | disclosed |
| US-20170065603-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-03-09 | — | — | US | disclosed |
| US-9546158-B2 | 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-01-17 | — | — | US | disclosed |
| US-9315490-B2 | 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-20160024053-A1 | Novel 2,5-Substituted Pyrimidines | GRUENENTHAL GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| WO-2011159857-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159857-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-2370407-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7812043-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| WO-2010080474-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| EP-1689392-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049019-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2005-06-02 | — | — | WO | disclosed |
| EP-1532980-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | GALK1, GCKR, GCK | GHSR 748/4885ALDH1A1 2638/4885HSD17B10 1492/4885 |
| US-20170065603-A1 | Novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | GHSR 4464/4885ALDH1A1 337/4885HSD17B10 1237/4885 |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | GCKR, GCK, GALK1 | GHSR 821/4885ALDH1A1 1240/4885HSD17B10 1000/4885 |
| US-20160024053-A1 | Novel 2,5-Substituted Pyrimidines | PDE4B, PDE4A, PDE12 | GHSR 4464/4885ALDH1A1 337/4885HSD17B10 1237/4885 |
| US-10391099-B2 | Method of treating psoriatic arthritis, psoriasis, and chronic obstructive pulmonary disease with a novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | GHSR 4702/4885ALDH1A1 334/4885HSD17B10 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.